Generics
Intas B2B portfolio is constantly growing across multiple therapeutic areas, specialized in CNS and Cardiovascular. Intas is also vertically integrated into some APIs (Active Pharmaceutical Ingredients)
Alimentary tract & Metabolism
Antiinfectives
Cardiovascular System
Dermatology
Genito-urinary System
Hematology
Hormonal System
Immunosuppression & Autoimmune Diseases
Musculo-skeletal System
Nervous System
Oncology
Ophtalmology
Respiratory System
KEY LAUNCHES
Enzalutamide sg capsules
Colombia 2022
Vietnam 2025
Philippines 2025
Apixaban early launches in
Brazil 2022
Canada 2022
UK 2023
Mitomycin launched in Japan in 2023
Tacrolimus Ointment
First to market in Australia in 2025
Nintedanib Day 1 launch in Europe in
2026
Apremilast Day 1 launch in Germany in 2026
Intas Intellectual Property department is one of the most important pillars for achieving ‘day one launches’, which ensures high-quality medicines are more accessible.
None of the products listed above are available for countries where the offer and/or supply of the product could be deemed an infringement of the intellectual property rights of third parties.
